Palvella Therapeutics
PVLA
140 hedge funds and large institutions have $1.02B invested in Palvella Therapeutics in 2025 Q4 according to their latest regulatory filings, with 53 funds opening new positions, 42 increasing their positions, 29 reducing their positions, and 12 closing their positions.
342% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 12
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
97% more call options, than puts
Call options by funds: $20.2M | Put options by funds: $10.2M
91% more capital invested
Capital invested by funds: $534M → $1.02B (+$487M)
45% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 29
40% more funds holding
Funds holding: 100 → 140 (+40)
5.37% more ownership
Funds ownership: 77.09% → 82.45% (+5.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SPPAM
Summit Partners Public Asset Management
Boston,
Massachusetts
|
+$30.2M |
| 2 |
State Street
Boston,
Massachusetts
|
+$24.2M |
| 3 |
Jennison Associates
New York
|
+$23.9M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$22.9M |
| 5 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$24.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$20.5M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$15.7M |
| 4 |
Goldman Sachs
New York
|
-$11.7M |
| 5 |
PA
Perceptive Advisors
New York
|
-$11M |
PVLA Hedge Fund Activity: Q4 2025 in Review
140 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q4 2025, worth a combined $1.02B — up 91% from $534M a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new PVLA positions and 12 closed out — a net gain of 41 holders — while 42 added to existing stakes and 29 trimmed.
The largest buyer was Summit Partners Public Asset Management, adding an estimated $30.2M. The largest seller was BVF Inc, cutting an estimated $24.1M.
- 140 institutional investors held Palvella Therapeutics (PVLA) as of Q4 2025, up from 100 in Q3 2025.
- Funds reported $1.02B of Palvella Therapeutics stock for Q4 2025, up 91% quarter-over-quarter.
- 53 funds opened new Palvella Therapeutics positions in Q4 2025 and 12 closed out, a net change of +41 holders.
- The largest Palvella Therapeutics buyer in Q4 2025 was Summit Partners Public Asset Management, an estimated $30.2M added.
- The largest Palvella Therapeutics seller in Q4 2025 was BVF Inc, an estimated $24.1M sold.
Based on aggregated 13F filings for Q4 2025.